Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Modalities › Small Molecule

Small Molecule (139 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare 2 Phase 3 $25.6M 3
ABVX Abivax Immunology 2 Phase 3 $7.50B 2
ACIU AC Immune Neurology Rare 6 Phase 3 $222M 11
ACHV Achieve Life Sciences — 2 NDA Submitted $692M 2
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 4 Phase 2 $619M 8
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 7 Phase 2 $69.0M 9
ACTU Actuate Therapeutics Oncology 4 Phase 2 $7.9M 4
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 6 Approved $1.76B 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 2 Phase 2 $376M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 7 Approved $111M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 5 NDA Submitted $38.3M 5
ATHE Alterity Therapeutics Neurology Rare 2 Phase 2 $46.4M 2
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.79B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 6 Phase 2 $151M 6
ANNX Annexon HematologyNeurology+2 Rare 1 Phase 3 $796M 6
RCUS Arcus Biosciences DermatologyImmunology+1 3 Phase 3 $2.63B 8
ARDX Ardelyx GI/HepatologyRenal 4 Approved $724M 4
ARVN Arvinas NeurologyOncology Rare 10 Approved $420M 10
ATAI Atai Beckley Neurology 5 Phase 2 $2.73B 5
AXSM Axsome Therapeutics Neurology Rare 15 Approved $6.96B 15
BLTE Belite Bio MetabolicOphthalmology Rare 6 NDA Submitted $6.21B 6
BIOA BioAge Labs CardiovascularOphthalmology 2 Phase 2 $245M 2
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 2 Approved $1.98B 4
BMEA Biomea Fusion MetabolicOncology 4 Phase 2 $41.1M 4
BDTX Black Diamond Therapeutics Oncology 4 Phase 2 $99.7M 4
BBOT BridgeBio Oncology Therapeutics Oncology 6 Phase 1 $164M 6
CCCC C4 Therapeutics Oncology 2 Phase 2 $407M 2
CRDL Cardiol Therapeutics Cardiovascular Rare 4 Phase 3 $121M 4
CRVO CervoMed Neurology Rare 4 Phase 2 $21.5M 4
CING Cingulate Neurology 1 NDA Submitted $61.9M 1
CLNN Clene Neurology Rare 5 NDA Submitted $56.9M 5
CLYM Climb Bio HematologyImmunology+1 Rare 1 Phase 2 $604M 8
COGT Cogent Biosciences HematologyOncology Rare 6 NDA Submitted $5.51B 7
CGTX Cognition Therapeutics Neurology 2 Phase 2 $65.3M 2
CMPS COMPASS Pathways Neurology 3 NDA Submitted $1.22B 3
CTNM Contineum Therapeutics NeurologyRespiratory Rare 4 Phase 2 $374M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 6 Phase 3 $889M 7
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 6 Approved — 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted $728M 10
DFTX Definium Therapeutics Neurology 4 Phase 3 $4.47B 4
IRON Disc Medicine GI/HepatologyHematology+2 Rare 3 Phase 3 $3.59B 9
EWTX Edgewise Therapeutics Cardiovascular 3 Phase 2 $4.93B 3
EIKN Eikon Therapeutics Oncology 13 Phase 2 $320M 13
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 4 Phase 2 $50.2M 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 7 Approved $320M 7
ELVN Enliven Therapeutics Oncology 1 Phase 1 $3.64B 1
ERAS Erasca Oncology 4 Phase 1 $5.04B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 13 Approved $1.63B 17
EVMN Evommune DermatologyImmunology+1 3 Phase 2 $241M 6
EXEL Exelixis CardiovascularOncology 17 Approved $17.0B 23
EYPT EyePoint Ophthalmology 2 Phase 3 $31.0M 2
FHTX Foghorn Therapeutics Oncology 1 Preclinical $111M 4
FBIO Fortress Biotech DermatologyHematology+3 Rare 8 Approved $61.7M 12
GANX Gain Therapeutics MetabolicNeurology Rare 4 Phase 1 $45.0M 5
GHRS GH Research NeurologyWomen's Health 4 Phase 2 $1.28B 4
GOSS Gossamer Bio Cardiovascular Rare 4 NDA Submitted — 4
GRCE Grace Therapeutics Neurology 1 NDA Submitted $38.9M 1
HRMY Harmony Biosciences MetabolicNeurology Rare 14 Approved $1.94B 17
HROW Harrow Ophthalmology Rare 11 Approved $1.01B 15
HELP Helus Pharma Neurology 3 Phase 3 $655M 3
IDYA IDEAYA Biosciences Oncology 11 NDA Submitted $3.02B 14
IMRX Immuneering Oncology 5 Phase 3 $238M 5
IMUX Immunic GI/HepatologyNeurology 4 Phase 3 $106M 4
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $9.15B 16
IMNM Immunome Oncology Rare 1 NDA Submitted $2.13B 9
IXHL Incannex Healthcare NeurologyRespiratory 2 Phase 2 $28.1M 2
INSM Insmed CardiovascularImmunology+3 Rare 9 Approved $25.1B 15
KAPA Kairos Pharma Oncology 3 Phase 2 — 13
KZIA Kazia Therapeutics NeurologyOncology Rare 9 Phase 2 $82.0M 13
KPRX Kiora Pharmaceuticals Ophthalmology Rare 4 Phase 3 $6.4M 4
KURA Kura Oncology MetabolicOncology 12 Approved $647M 12
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 5 Phase 2 $11.2B 5
LBRX LB Pharmaceuticals Neurology 3 Phase 3 $1.36B 3
LENZ LENZ Therapeutics Ophthalmology 1 Approved $110M 1
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 1 Phase 2 $237M 12
LQDA Liquidia CardiovascularImmunology+1 Rare 9 Approved $3.97B 9
MAIA MAIA Biotechnology Oncology 7 Phase 3 $64.5M 7
MPLT MapLight Therapeutics Neurology 6 Phase 2 $385M 6
MAZE Maze Therapeutics MetabolicRenal Rare 4 Phase 2 $1.90B 4
MIST Milestone Pharmaceuticals Cardiovascular 2 Approved $95.0M 2
MLYS Mineralys Therapeutics CardiovascularRenal+1 3 NDA Submitted $1.36B 3
MBRX Moleculin Biotech Oncology 8 Phase 2 — 8
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 7 Phase 2 $903M 7
NGEN NervGen Pharma Neurology 1 Phase 3 $143M 3
NRSN NeuroSense Therapeutics Neurology Rare 3 Phase 2 $3.2M 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 6 NDA Submitted $2.27B 6
NRXP NRX Pharmaceuticals Neurology Rare 6 Approved $103M 7
NRIX Nurix Therapeutics ImmunologyNeurology+1 13 Phase 3 $1.67B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 9 Phase 3 $719M 9
OCS Oculis Holding NeurologyOphthalmology Rare 3 Phase 3 $417M 5
OLMA Olema Pharmaceuticals Oncology 3 Phase 3 $641M 3
OMER Omeros HematologyNeurology+2 Rare 2 Approved $1.22B 6
OKUR OnKure Therapeutics Oncology 2 Preclinical $116M 2
IRD Opus Genetics Ophthalmology Rare 4 Approved $348M 12
ORIC Oric Pharmaceuticals Oncology 5 Phase 3 $914M 5
OVID Ovid Therapeutics Neurology Rare 4 Phase 2 $557M 4
PTN Palatin Technologies ImmunologyMetabolic+1 Rare 4 Phase 3 $11.2M 8
PALI Palisade Bio Immunology 2 Phase 2 $197M 3
KTTA Pasithea Therapeutics NeurologyOncology Rare 4 Phase 1 $19.3M 4
PMVP PMV Pharmaceuticals Oncology 7 Phase 2 $67.4M 7
PYPD PolyPid Infectious DiseaseOncology 3 NDA Submitted $125M 3
PRLD Prelude Therapeutics HematologyOncology Rare 3 Phase 1 $287M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 7 Phase 2 $5.4M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 1 Approved $8.62B 12
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $142M 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 4 Phase 2 $257M 4
RAPP Rapport Therapeutics Neurology 10 Phase 3 $1.45B 10
RXRX Recursion Pharmaceuticals Oncology 6 Phase 2 $2.19B 6
RLAY Relay Therapeutics DermatologyOncology Rare 4 Approved $4.11B 4
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 4 Phase 2 $416M 4
RVPH Reviva Pharmaceuticals CardiovascularDermatology+2 Rare 10 Phase 3 $4.8M 10
RVMD Revolution Medicines Oncology 11 Approved $41.6B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved $7.78B 14
SGMT Sagimet Biosciences DermatologyMetabolic 3 Phase 3 $698M 3
SCYX Scynexis Infectious DiseaseRenal Rare 5 Approved $34.8M 5
SLS SELLAS Life Sciences Group Oncology 4 Phase 3 $1.70B 9
SEPN Septerna ImmunologyMetabolic+1 Rare 5 Phase 1 $2.28B 5
SION Sionna Therapeutics Respiratory Rare 5 Phase 2 $148M 5
GPCR Structure Therapeutics MetabolicRespiratory Rare 5 Phase 3 $4.35B 5
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 6 Approved $852M 7
TNGX Tango Therapeutics Oncology 4 Phase 1 $3.63B 4
TLX Telix Pharmaceuticals Oncology 14 Approved $3.27B 25
TENX Tenax Therapeutics Cardiovascular Rare 2 Phase 3 $77.0M 2
TVTX Travere Therapeutics MetabolicRenal Rare 6 Approved $4.76B 7
TTRX Turn Therapeutics DermatologyInfectious Disease Rare 3 Phase 2 $282M 4
TYRA Tyra Biosciences MetabolicOncology Rare 5 Phase 2 $1.26B 5
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 2 Approved $1.57B 10
UNCY Unicycive Therapeutics Renal 2 NDA Submitted $98.9M 2
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 23 Approved $231M 27
VSTM Verastem Oncology 5 Approved $1.06B 5
VRCA Verrica Pharmaceuticals DermatologyOncology 2 Approved $54.8M 3
VKTX Viking Therapeutics MetabolicNeurology Rare 4 Phase 3 $3.42B 9
VYGR Voyager Therapeutics MetabolicNeurology Rare 4 Phase 1 $116M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 9 Phase 3 $84.4M 9
XFOR X4 Pharmaceuticals — 2 Approved $325M 2
XENE Xenon Pharmaceuticals Neurology Rare 9 NDA Submitted $3.79B 9
XERS Xeris Biopharma MetabolicNeurology Rare 3 Approved $2.78B 4
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 4 NDA Submitted $1.92B 11
ZNTL Zentalis Pharmaceuticals Oncology 1 Phase 3 $123M 1